Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are conducting a non-interventional, multi-site observational study to collect real-world data on the use of an autologous, hair follicle derived secretome topical cosmetic product. This product is applied following various medical aesthetic procedures to assess its effects on post-procedural erythema and recovery. The study is open-label and involves participants aged 18 to 60 undergoing specific aesthetic treatments. Participants plan to use the Acorn Autologous Hair Follicle Secretome cosmetic product as an adjunct after medical aesthetic procedures such as laser resurfacing ablative or non-ablative, Tixel treatment of the face, and treatment of acne or surgical scars combined with other procedures like microneedling or ablative laser. Some scalp treatments and Ellacor procedures are closed to enrollment. The study does not involve any experimental interventions but observes the real-world application of this topical product. During the study, participants will be monitored for symptoms and downtime after their procedures using questionnaires over 1 to 7 days post-treatment. Researchers will collect data on post-procedure symptoms and recovery time to evaluate the products impact. The total study period extends until February 2027, with ongoing assessments at specified intervals to capture real-world outcomes and safety information.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
This observational study focuses on adults with actinic keratosis AK lesions on the face who are already using tirbanibulin as part of their regular care. The study aims to learn how tirbanibulin affects the overall appearance, look, and texture of the skin over a 57-day period. Researchers want to understand patient and clinician perspectives on skin improvement after treatment. Participants will apply tirbanibulin ointment 1% 3.5 mg in 350 mg once daily for five consecutive days using a single-dose packet. After the treatment, participants will be observed for 57 days to gather patient-reported outcomes and clinical information. The study involves no placebo or comparator groups and focuses on real-world use of the medication. During the study, participants will complete online surveys at the start and at day 57 to assess skin appearance and satisfaction with treatment effects. Researchers will evaluate outcomes including ratings by subjects and clinicians on skin appearance, improvement in skin look and texture, and clinical clearance of AK lesions. The entire study period lasts 57 days, with no additional long-term follow-up mentioned.
Actively Recruiting
Researchers are evaluating the effectiveness and long-term safety of PP405, a medicated topical gel, for treating Androgenetic Alopecia in adult males aged 18 to 55. This phase 23 randomized, double-blind study involves men who have experienced hair loss for at least six months and have specific severity scores on the Norwood-Hamilton scale. Participants are randomly assigned to receive either PP405 topical gel or a non-medicated vehicle gel applied to the scalp once daily for 24 weeks. After this initial period, those on PP405 continue the treatment while participants initially on the vehicle are re-randomized to either PP405 or vehicle for an additional 28 weeks, creating a total treatment duration of 52 weeks to assess both efficacy and safety over time. Throughout the study, participants will be regularly assessed for changes in hair count and scalp coverage using both clinical and participant evaluations at weeks 12 and 24. Safety monitoring continues during the extension phase up to week 52. The primary outcome focuses on the change in non-vellus target area hair count at week 24, with secondary measures including participant assessments of scalp coverage and hair count improvements at weeks 12 and 24.
Actively Recruiting
Researchers are evaluating the safety, how the body absorbs and processes, and the treatment effects of CABTREO lotion when applied to the skin in children aged 9 to 11 years, 11 months who have moderate to severe acne vulgaris. The study is open-label and phase 4, focusing on pediatric participants with specific acne severity and lesion counts on the face and at least one trunk area. The purpose is to understand how well CABTREO works and how safe it is in this age group. Participants will apply CABTREO, a combination gel containing clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15%, to affected areas once each morning for 12 weeks. On study visit days, participants will apply the gel at the study center after assessments. The study includes a main group and a smaller pharmacokinetics PK sub-study group to examine drug levels in the blood. The treatment is a topical gel gently rubbed into the skin. Participants will first complete a screening period of up to 5 weeks to confirm eligibility. During the 12-week treatment, they will attend visits at baseline and Days 14, 15 PK sub-study only, 28, 29 PK sub-study only, 56, and 84. Researchers will monitor safety by tracking any adverse events and measure changes in inflammatory and non-inflammatory acne lesions, as well as global acne severity scores. Participants must follow study instructions and attend visits with their parent or guardian if under age of consent.